NIP
RYTM icon

Nicholas Investment Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Nicholas Investment Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5M Buy
+139,270
New +$12.6M 0.87% 35
2026
Q1 		– Sell
-34,710
Closed -$3.72M – 226
2025
Q4 		$3.72M Buy
+34,710
New +$3.68M 0.27% 127

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nicholas Investment Partners's RYTM Position: Q2 2026 in Review

Nicholas Investment Partners opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 139,270 shares worth $15.5M. The stake represents 0.87% of the portfolio and ranks #35 among its holdings. This is a return to the name: Nicholas Investment Partners previously reported a position in RYTM as recently as Q4 2025.

Nicholas Investment Partners first reported a position in RYTM in Q4 2025 and has held it in 2 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Nicholas Investment Partners held 139,270 shares of Rhythm Pharmaceuticals worth $15.5M as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Nicholas Investment Partners position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.87% of Nicholas Investment Partners's portfolio in Q2 2026, its #35 holding.
  • Nicholas Investment Partners first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.